Bone Abstracts

Pharmacologic treatment of patients with a high risk of fracture is mandatory. Nowadays there are many available options mostly with antiresorptive agents (bisphosphonates, SERMs, strontium ranelate, calcitonin, estrogens and denosumab) but also with anabolic agents (teriparatide) that have shown to reduce incidence of new fragility fractures. In the near future new drugs targeting different pathways and mediators involved in bone remodelling will be available.

At present, choice of agent will depend on osteoporosis severity but also on drug availability, comorbidities, cost and patient preference. Controversial and unanswered issues are the risk of possible long term side effects of these drugs, duration of treatment and drug holidays as well as the possible use sequential or combined treatment modalities.

The goal of this session is to discuss present and evolving guidelines and treatment modalities. At the end of the meeting participants will be able to:

– Apply current osteoporosis treatment guidelines in a clinical setting.

– Understand the safety and efficacy issues of current and emerging osteoporosis treatments.

– Recognize and overcome the current gaps in osteoporosis treatment.